Long-Term 3-Year Efficacy of Dupilumab in QUEST Patients Enrolled in LIBERTY ASTHMA TRAVERSE

被引：0
|
作者：
Papi, A. [1 ]
Bourdin, A. [2 ]
Watz, H. [3 ]
Pavord, I. D. [4 ]
Domingo, C. [5 ]
Wechsler, M. E. [6 ]
Mao, X. [7 ]
Ortiz, B. [8 ]
Djandji, M. [9 ]
Mannent, L. P. [10 ]
Ruddy, M. [8 ]
Laws, E. [7 ]
Amin, N. [8 ]
Lederer, D. J. [8 ]
Hardin, M. [9 ]
机构：
[1] Univ Ferrara, S Anna Univ Hosp, Resp Med Unit, Ferrara, Italy
[2] Montpellier Univ Hosp, Montpellier, France
[3] German Ctr Lung Res DZL, Airway Res Ctr North ARCN, LungenClin Grosshansdorf, Pulm Res Inst, Grosshansdorf, Germany
[4] Univ Oxford, NIHR Oxford Biomed Res Ctr, Oxford, England
[5] Autonomous Univ Barcelona, Sabadell, Corp Sanitaria Parc Tauli, Barcelona, Spain
[6] Natl Jewish Hlth, Denver, CO USA
[7] Sanofi, Bridgewater, NJ USA
[8] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
[9] Sanofi, Cambridge, MA USA
[10] Sanofi, Chilly Mazarin, France
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2021年 / 203卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A1460
引用
收藏
页数：1
相关论文
共 50 条
  • [1] LONG-TERM EFFICACY OF DUPILUMAB: 3-YEAR DATA OF QUEST PATIENTS WITH MODERATE-TO-SEVERE ASTHMA ENROLLED IN LIBERTY ASTHMA TRAVERSE
    Pavord, I. D.
    Papi, A.
    Bourdin, A.
    Watz, H.
    Domingo, C.
    Wechsler, M. E.
    Mao, X.
    Ortiz, B.
    Djandji, M.
    Mannent, L.
    Laws, E.
    Amin, N.
    Lederer, D. J.
    Hardin, M.
    THORAX, 2021, 76 : A53 - A54
  • [2] Long-Term Efficacy of Dupilumab in Patients With Asthma With an Allergic Phenotype Rolled Over From LIBERTY ASTHMA QUEST: LIBERTY ASTHMA TRAVERSE Study
    Sher, Lawrence
    Corren, Jonathan
    Pavord, Ian
    Daizadeh, Nadia
    Ortiz, Benjamin
    Djandji, Michel
    Deniz, Yamo
    Rowe, Paul
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (02) : AB60 - AB60
  • [3] Late Breaking Abstract - Dupilumab long-term safety and efficacy in patients with asthma: LIBERTY ASTHMA TRAVERSE
    Wechsler, Michael E.
    Ford, Linda B.
    Maspero, Jorge F.
    Pavord, Ian D.
    Tohda, Yuji
    Langton, David
    Domingo, Christian
    Papi, Alberto
    Bourdin, Arnaud
    Watz, Henrik
    Park, Hae Sim
    Chapman, Kenneth R.
    Mao, Xuezhou
    Ortiz, Benjamin
    Djandji, Michel
    Kapoor, Upender
    Khokhar, Faisal A.
    Mannent, Leda P.
    Ruddy, Marcella
    Laws, Elizabeth
    Amin, Nikhil
    Hardin, Megan
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [4] Long-term efficacy of dupilumab in patients with type 2 asthma by age at onset: LIBERTY ASTHMA TRAVERSE
    Busse, W. W.
    Kraft, M.
    Domingo, C.
    De Mir, I.
    Maselli, D. J.
    Soler, X.
    Xia, C.
    Pandit-Abid, N.
    Jacob-Nara, J. A.
    Sacks, H.
    Rowe, P. J.
    Deniz, Y.
    ALLERGOLOGIE, 2023, 46 (08) : 543 - 544
  • [5] Long-Term Dupilumab Efficacy in Patients with Type 2 Asthma by Age of Onset: Liberty asthma traverse
    Busse, William
    Kraft, Monica
    Domingo, Christian
    De Mir, Ines
    Maselli, Diego J.
    Soler, Xavier
    Xia, Changming
    Pandit-Abid, Nami
    Jacob-Nara, Juby A.
    Sacks, Harry
    Rowe, Paul J.
    Deniz, Yamo
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [6] LONG-TERM EFFICACY OF DUPILUMAB IN ORAL CORTICOSTEROID-DEPENDENT PATIENTS WITH ASTHMA: LIBERTY ASTHMA TRAVERSE
    Sher, Lawrence
    Wechsler, Michael
    Rabe, Klaus
    Maspero, Jorge
    Daizadeh, Nadia
    Mao, Xuezhou
    Ortiz, Benjamin
    Mannent, Leda
    Laws, Elizabeth
    Ruddy, Marcella
    Pandit-Abid, Namrata
    Lederer, David
    Hardin, Megan
    CHEST, 2021, 160 (04) : 1882A - 1884A
  • [7] LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS WITH ASTHMA: LIBERTY ASTHMA TRAVERSE OPEN-LABEL EXTENSION STUDY
    Pavord, Id
    Wechsler, Me
    Domingo, C.
    Papi, A.
    Bourdin, A.
    Watz, H.
    Mao, X.
    Kapoor, U.
    Khokhar, Fa
    Mannent, Lp
    Ruddy, M.
    Laws, E.
    Amin, N.
    Hardin, M.
    THORAX, 2021, 76 : A81 - A82
  • [8] Impact of age of asthma onset on the long-term efficacy of Dupilumab in patients with type 2 inflammation: Liberty asthma traverse study
    Busse, W. W.
    Kraft, M.
    Domingo, C.
    De Mir, I.
    Maselli, D.
    Soler, X.
    Xia, C.
    Pandit-Abid, N.
    Jacob-Nara, J. A.
    Sacks, H.
    Rowe, P. J.
    Deniz, Y.
    ALLERGY, 2023, 78 : 54 - 55
  • [9] Long-term dupilumab efficacy across biomarker quadrants in asthma patients: TRAVERSE
    Wechsler, M.
    Pavord, I
    Papi, A.
    Chapman, K.
    Mao, X.
    Ortiz, B.
    Djandji, M.
    Jacob-Nara, J.
    Rowe, P.
    Deniz, Y.
    Laws, E.
    Akinlade, B.
    Amin, N.
    Lederer, D.
    Hardin, M.
    RESPIROLOGY, 2022, 27 : 112 - 113
  • [10] Assessment of Long-Term Maintenance of OCS Reduction and Efficacy in the Dupilumab LIBERTY ASTHMA TRAVERSE Extension Study
    Sher, L.
    Wechsler, M.
    Rabe, K. F.
    Maspero, J. F.
    Daizadeh, N.
    Mao, X.
    Ortiz, B.
    Mannent, L. P.
    Laws, E.
    Ruddy, M. K.
    Pandit-Abid, N.
    Lederer, D. J.
    Hardin, M. E.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
12345